Moleculin Signs a Clinical Research Agreement with Emory University for Brain Tumor in Pediatric Patients

 Moleculin Signs a Clinical Research Agreement with Emory University for Brain Tumor in Pediatric Patients

Moleculin Signs a Clinical Research Agreement with Emory University for Brain Tumor in Pediatric Patients

Shots:

  • Moleculin collaborated with Emory University to conduct P-I trial for WP1066 to treat recurrent or refractory malignant brain tumors in pediatric patients
  • The trial will be conducted at Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta, with its expected recruitment in H2’19
  • WP1066 is an immuno-stimulating STAT3 inhibitor will be evaluated in P-I and is developed for targeting brain tumors, pancreatic cancer and AML

Click here to read full press release/ article | Ref: Moleculin | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post